Innate Pharma's market cap is currently ―. The company's EPS TTM is $-0.101; its P/E ratio is -23.22; Innate Pharma is scheduled to report earnings on September 12, 2024, and the estimated EPS forecast is $-0.38. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Jun 22	Dec 21	Jun 21
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	€ 92.46M	€ 84.22M	€ 123.35M	€ 119.84M	€ 119.32M
Total Assets	€ 184.21M	€ 207.86M	€ 280.43M	€ 267.50M	€ 266.22M
Total Debt	€ 47.54M	€ 0.00	€ 43.37M	€ 44.25M	€ 16.50M
Net Debt	€ -44.92M	€ -84.22M	€ -79.98M	€ -75.58M	€ -102.82M
Total Liabilities	€ 132.29M	€ 156.44M	€ 164.10M	€ 160.06M	€ 132.66M
Stockholders Equity	€ 51.90M	€ 379.64M	€ 116.33M	€ 107.44M	€ 133.56M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in EUR

Innate Pharma Earnings and Revenue History

Income Statement >

Innate Pharma Debt to Assets

Balance Sheet >

Innate Pharma Cash Flow

Cash Flow >

Innate Pharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing